ClinicalTrials.govcontrolled
Phase II Study of Tislelizumab Combined With Cetuximab and Irinotecan in the Treatment of Recurrent, Refractory mCRC
ClinicalTrials.gov study NCT05143099. IPD Sharing: YES. Countries: 1. Publications: 0.
ShareScore
24/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 0
- Reuse readiness
- 0
- Engagement
- 4
Topics
Dataset details
- Repository
- ClinicalTrials.gov
- Published
- February 11, 2026
- License
- IPD-YES
- DOI
- clinicaltrials.gov/NCT05143099
Scored with release 0.9.0
ScienceDex for faculty
Your academic CV and NIH biosketch
Make your CV in your school's format and your NIH biosketch from it, then download both as Word files.